Precision BioSciences Appoints Rare Disease Executive Shalini Sharp to Its Board of Directors
Precision BioSciences, a genome editing company dedicated to improving life, announced today that industry veteran Shalini Sharp has joined the company’s Board of Directors. An established business leader in the life sciences industry, Sharp is the Chief Financial Officer (CFO) and Executive Vice President of Ultragenyx Pharmaceutical. Sharp brings a wealth of experience in financial management and corporate strategy in rare disease, gene therapy and oncology.
“We are thrilled to welcome Shalini Sharp to the Precision BioSciences Board of Directors,” said Precision CEO Matt Kane. “Shalini’s broad understanding of the financial markets within rare disease and oncology will be invaluable as Precision progresses into clinical trials of its genome-edited product portfolio.”
“I am excited to work with Precision as the company develops new therapies based on its next generation gene editing technology, ARCUS, which has the potential to help patients achieve better outcomes,” said Sharp. “I have also been impressed by the scaled manufacturing process Precision has developed, which is a critical and sometimes overlooked factor.”
As CFO of Ultragenyx, a pharmaceutical company creating therapies for rare diseases, Sharp leads corporate finance, strategy and information technology. She previously served as CFO and board member of Agenus, a biotechnology company focused on cancer immunotherapies. Before that, she worked in corporate strategy at Elan Pharmaceuticals, in management consulting at McKinsey & Company and in investment banking at Goldman Sachs, always in the pharmaceutical and medical device space. Sharp holds a BA and an MBA from Harvard University. An experienced corporate leader, she is also a board member at Sutro Biopharma and Array Biopharma.
About Precision BioSciences
Precision BioSciences is dedicated to improving life. Our mission is to cure genetic disease, overcome cancer, and feed the planet. We are striving to achieve this goal with ARCUS, our therapeutic-grade, naturally-derived genome editing platform, to help overcome life’s greatest genetic challenges. For additional information, please visit www.precisionbiosciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181220005338/en/